Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
H Magnussen(LungenClinic Grosshansdorf), Peter M.A. Calverley(University of Liverpool), Lesley Towse(Boehringer Ingelheim (United Kingdom)), Emiel F.�M. Wouters(Maastricht University), Pascal Chanez(Aix-Marseille Université), Henrik Watz(University of Lübeck), Kay Tetzlaff(Boehringer Ingelheim (Taiwan)), Ronald Dahl(Aarhus University Hospital), Anne Kirsten(German Center for Lung Research), Roberto Rodríguez-Roisin(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Bernd Disse(Boehringer Ingelheim (Taiwan)), Marc Decramer(KU Leuven), Helen Finnigan(Boehringer Ingelheim (South Korea))
Cited by 621
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation
|American Journal of Respiratory and Critical Care Medicine|2013|3.8k
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
|New England Journal of Medicine|2010|3k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation
|American Journal of Respiratory and Critical Care Medicine|2006|2k